Latest News and Press Releases

Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancerExpert clinical centers already involved worldwide in this new Innovation...

HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil Marseille, France, December 10, 2020 HalioDx SAS, the immuno-oncology...

Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients Marseille, France, December 03, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological...

New data reinforces Immunoscore clinical utility  in localized Colon Cancer Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...

Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9,...

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...

Immunoscore® included in ESMO Clinical Practice Guidelines 2020 Marseille, France, August 06, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been...

New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of...

Immunoscore® in the WHO Classification of Digestive System Tumours Immune response is  now part of the Essential and Desirable Diagnostic Criteria for Colorectal Cancers in the 5th edition of the...

Immunoscore® to support Immuno-oncology and microbiome research within the ONCOBIOME consortium A 15M€ European granted consortium led by Laurence Zitvogel from Gustave Roussy in Villejuif.HalioDx...